POROS™ MabCapture™ A Affinity Chromatography Resin

POROS MabCapture A Media is a new design in Protein A chromatography resins technology, combining improvements made in bead and chemistry technology. These advances provide a monoclonal antibody purification resins that not only demonstrates the highest dynamic binding performance at low flow rates but also one that can maintain superior binding capacity at high linear velocities where other chromatography resins products cannot operate.

With POROS MabCapture affinity chromatography resins you can:

• Obtain the highest dynamic binding capacity for monoclonal antibodies vs. conventional agarose or silica based Protein A medias
• Maintain high dynamic binding capacity at flow rates over 700 cm/hr
• Design processes with greater flexibility (shorter bed heights, faster flow rates or both) due to the improvements made to the antibody binding efficiency
• Clean and sanitize with standard sodium hydroxide agents utilized for other chromatography products
• Recognize major increases to process productivity and reduce the downstream bottleneck

The development of humanized monoclonal antibodies has continued to fuel the growth of the biotherapeutic market. Addressing the therapeutic demand for monoclonal antibodies has lead to major improvements to the cell based expression systems that are used to manufacture these proteins. Consequently, these improvements have moved the processing bottleneck from upstream cell expression to the downstream purification process, as the purification operations struggle to keep up with the large quantities of antibodies that need to be manufactured.

Protein A chromatography, which is used as the primary capture chromatography step in most antibody process platforms, is generally regarded as the major process bottleneck due to the slow flow rates and long residence times required for the effective operation of conventional Protein A chromatography medias.The introduction of POROS MabCapture chromatography resins is aimed at cracking open the downstream bottleneck and providing the capacity, efficiency and flexibility needed to make improvements to the downstream purification platform resulting in major increases to process productivity and antibody manufacturing.